Last Updated 00:00:00
Company Encyclopedia
View More
Dizal Pharmaceutical
688192.SH
Dizal (Jiangsu) Pharmaceutical Co., Ltd., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of oncology and hematologic disorders. Its assets include the ZEGFROVY, for the treatment of solid tumors; Gao Ruizhe to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematological malignancy and solid tumors. Dizal (Jiangsu) Pharmaceutical Co., Ltd. was founded in 2017 and is based in Shanghai, China.
1.470 T
688192.SHMarket value -Rank by Market Cap -/-
Valuation analysis
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
- P/E
- Price
- High
- Median
- Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
- P/B
- Price
- High
- Median
- Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
- P/S
- Price
- High
- Median
- Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
- Dividend Yield
- Price
- High
- Median
- Low
Institutional View & Shareholder
Analyst Ratings
- Price--
- Highest--
- Lowest--